Unknown

Dataset Information

0

Combined agonists act synergistically to increase mucociliary clearance in a cystic fibrosis airway model.


ABSTRACT: Mucus clearance, a primary innate defense mechanism of airways, is defective in patients with cystic fibrosis (CF) and CF animals. In previous work, the combination of a low dose of the cholinergic agonist, carbachol with forskolin or a β adrenergic agonist, isoproterenol synergistically increased mucociliary clearance velocity (MCCV) in ferret tracheas. Importantly, the present study shows that synergistic MCCV can also be produced in CF ferrets, with increases ~ 55% of WT. Synergistic MCCV was also produced in pigs. The combined agonists increased MCCV by increasing surface fluid via multiple mechanisms: increased fluid secretion from submucosal glands, increased anion secretion across surface epithelia and decreased Na+ absorption. To avoid bronchoconstriction, the cAMP agonist was applied 30 min before carbachol. This approach to increasing mucus clearance warrants testing for safety and efficacy in humans as a potential therapeutic for muco-obstructive diseases.

SUBMITTER: Joo NS 

PROVIDER: S-EPMC8458446 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5516211 | biostudies-literature
| S-EPMC6322033 | biostudies-literature
| S-EPMC6053331 | biostudies-literature
| S-EPMC6481377 | biostudies-literature
| S-EPMC7197699 | biostudies-literature
| S-EPMC6338313 | biostudies-literature
| S-EPMC3180295 | biostudies-literature
| S-EPMC4286667 | biostudies-literature
2020-06-01 | GSE99862 | GEO
| S-EPMC8102682 | biostudies-literature